Susan E. Quaggin - 30 Jun 2026 Form 4 Insider Report for AbbVie Inc. (ABBV)

Reporting relationship: Director
Issuer ticker: ABBV
Reported as of: 30 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2026, 17:00:12 UTC
Prior SEC filing: 12 May 2026
Source filing: View source filing
Reporting owner signature: /s/ T.O. Odutayo, Attorney-in-Fact for Susan E. Quaggin

Key filing fact

Susan E. Quaggin filed Form 4 for AbbVie Inc. (ABBV) on 02 Jul 2026.

Key facts

This page summarizes Susan E. Quaggin's Form 4 filing for AbbVie Inc. (ABBV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2026, 17:00.

Change

Previous filing in this sequence was filed on 12 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001997505 Primary reporting owner

Quaggin Susan E

Relationship: Director
Address: 1 N. WAUKEGAN ROAD, NORTH CHICAGO
Signature: /s/ T.O. Odutayo, Attorney-in-Fact for Susan E. Quaggin
Signature date: 02 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABBV transaction Derivative

Stock Equivalent Units

Award

Transaction value
Shares: +62
Change %: +7.8%
Price: $251.64^*
Shares after: 853
Date: 30 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 62
Exercise price: $251.64
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

Footnote F2

Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.